{"entity":{"id":"nct05827796","kind":"trial","name":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of IN10018 and Gemcitabine in pancreatic ductal adenocarcinoma, run by InxMed (Shanghai) Co., Ltd., now recruiting.","summary":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05827796 by InxMed (Shanghai) Co., Ltd., with 70 participants planned, started 2022-12-08 and due to reach its primary completion in 2025-12-31. Interventions recorded: IN10018, Albumin-Bound Paclitaxel, Gemcitabine and KN046.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05827796","url":"https://clinicaltrials.gov/study/NCT05827796"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["in10018","gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05827796","phase":"1/2","setting":"A Phase Ib/II, Open-label Clinical Study to Evaluate the Safety, Tolerability and Antitumor Activities of IN10018+Standard Chemotherapy and IN10018+Standard Chemotherapy+KN046 in Subjects With Advanced Pancreatic Cancer","sponsor":"InxMed (Shanghai) Co., Ltd.","enrolled":70,"outcomes":[]},"route":"/trials/nct05827796/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"}]}}